India, April 22 -- Within just seven months of its March 2025 launch, Mounjaro, the drug used for type 2 diabetes and weight loss, became the country's highest-selling medicine by value. Marketed by US pharmaceutical giant Eli Lilly and Company, it recorded sales of Rs.114 crore in March 2026 alone, as reported by Business Standard.

However, this rapid rise has also opened the door to illegal activity. Authorities recently seized counterfeit Mounjaro worth Rs.56 lakh in Gurugram, exposing a racket manufacturing and distributing fake injections. The development raises serious health concerns, as counterfeit versions may contain incorrect or harmful substances.

Mounjaro is currently manufactured exclusively by Eli Lilly, as the patent is ...